Certara (NASDAQ:CERT) Releases FY24 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.41-0.46 for the period, compared to the consensus estimate of $0.43. The company issued revenue guidance of $385-400 million, compared to the consensus revenue estimate of $388.90 million.

Analysts Set New Price Targets

A number of research firms recently weighed in on CERT. KeyCorp upgraded shares of Certara from a sector weight rating to an overweight rating and set a $23.00 price objective on the stock in a research report on Wednesday, April 10th. SVB Leerink started coverage on shares of Certara in a research report on Monday, February 26th. They set a market perform rating and a $19.00 target price on the stock. Leerink Partnrs restated a market perform rating on shares of Certara in a research report on Monday, February 26th. UBS Group boosted their target price on shares of Certara from $17.00 to $20.00 and gave the stock a neutral rating in a research report on Friday, March 1st. Finally, JMP Securities started coverage on shares of Certara in a research report on Thursday, April 4th. They set a market perform rating on the stock. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Hold and a consensus price target of $20.06.

Certara Stock Up 0.4 %

NASDAQ:CERT traded up $0.07 during trading hours on Friday, hitting $17.13. The stock had a trading volume of 96,499 shares, compared to its average volume of 532,812. The company has a current ratio of 2.62, a quick ratio of 2.62 and a debt-to-equity ratio of 0.28. Certara has a 1-year low of $11.81 and a 1-year high of $22.65. The business has a 50 day simple moving average of $17.71 and a two-hundred day simple moving average of $16.45. The company has a market cap of $2.74 billion, a PE ratio of -49.00, a price-to-earnings-growth ratio of 1.81 and a beta of 1.61.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.04). Certara had a negative net margin of 15.62% and a positive return on equity of 4.33%. The firm had revenue of $88.01 million during the quarter, compared to analyst estimates of $86.80 million. Analysts predict that Certara will post 0.29 EPS for the current year.

Insider Transactions at Certara

In other news, SVP Richard M. Traynor sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $18.00, for a total transaction of $54,000.00. Following the completion of the sale, the senior vice president now owns 173,524 shares of the company’s stock, valued at $3,123,432. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Richard M. Traynor sold 3,000 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $18.00, for a total transaction of $54,000.00. Following the transaction, the senior vice president now directly owns 173,524 shares in the company, valued at $3,123,432. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patrick F. Smith sold 14,427 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the transaction, the insider now owns 50,091 shares in the company, valued at $844,033.35. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,427 shares of company stock valued at $405,095. 2.39% of the stock is currently owned by corporate insiders.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.